DIRS.INFO The most relevant business & tech news

☆ Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance
▼ + stars: | 2024-10-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, and slashed its full-year adjusted profit guidance. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. Eli Lilly also lowered the high-end of its revenue outlook for the year and now expects sales of between $45.4 billion and $46 billion. The weekly injection raked in $1.26 billion in sales for the period, below the $1.76 billion that analysts expected, according to StreetAccount. As of Wednesday, the Food and Drug Administration's drug database said all doses of Zepbound and Mounjaro are available in the U.S. after extended shortages.

Persons: Eli Lilly, Mounjaro, Eli Lilly's Organizations: Novo Nordisk, LSEG, Food Locations: U.S

☆ Novo and Eli contender Zealand Pharma heralds its obesity drug alternative: It's our 'crown jewel'
▼ + stars: | 2024-10-11 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

Jaap Arriens | NurPhotoDanish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly . Last month, Zealand Pharma announced positive top-line results from a phase 1b trial of its weight-loss drug, a GLP-1/GLP-2 receptor dual agonist called Dapiglutide. Stock Chart Icon Stock chart icon Zealand Pharma. Novo Nordisk is also experimenting with its own version of the treatment, combining the GLP-1 component Semaglutide with amylin analog Cagrilintide in a candidate called CagriSema. Syringes from weight loss drugs "Wegovy," "Ozempic" and "Mounjaro."

Persons: Jaap Arriens, Eli Lilly, Adam Steensberg, Steensberg Organizations: Zealand Pharma, Novo Nordisk, CNBC, pharma, Nordisk, Union, Getty Locations: U.S

Several analysts raised their ratings and price targets on Starbucks a day after news that Chipotle CEO would take over at the coffee chain. Starbucks shares rallied on the news, while Chipotle shares fell. He also lowered his price target on shares to $685 from $750, which implies just 6% upside from Monday's close. Chipotle shares pulled back of 7% comes as decelerating trends and a sector rotation already impacted Chipotle's multiple. Since Niccol took the position of CEO in 2018, Chipotle shares surged more than 770%.

Persons: Bernstein, Fatima Boolani, Boolani, — Hakyung Kim, Eli Lilly Eli Lilly's, Berenberg, Lilly, Kerry Holford, " Holford, Morgan Stanley, Keith Weiss, Weiss, Hakyung Kim, Brian Niccol's, Danilo Gargiulo, Gargiulo, Niccol, Chipotle, Laxman Narasimhan, Brian Niccol, Baird, David Tarantino, Fred Imbert Organizations: CNBC, Citi, Palo Alto, Palo Alto Networks, pharma, Intuit, Starbucks, Deutsche Bank, SBUX Locations: Tuesday's

☆ Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
▼ + stars: | 2024-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

Shares of Eli Lilly closed more than 9% higher on Thursday. That has forced Eli Lilly and its rival Novo Nordisk to invest heavily to boost manufacturing. "We just see unbelievable demand, and we're not even trying that hard to promote this drug," Eli Lilly CEO David Ricks told CNBC in an interview. Eli Lilly said sales were largely driven by higher demand for Mounjaro and Zepbound as production increases improved supply in the U.S. With a market cap of more than $730 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, Eli Lilly's, we're, David Ricks, Ricks, Zepbound, Mounjaro, Wegovy Organizations: U.S, Novo Nordisk, Food, CNBC, LSEG Locations: U.S, United States, Novo

☆ Eli Lilly's second quarter eases Zepbound pricing fears and suggests it's making headway in weight loss race
▼ + stars: | 2024-08-08 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Lilly's shares are up more than 7% on the news. LLY YTD mountain Eli Lilly shares year to date. The first followed positive reports from rivals that showed they were making progress in developing their own weight loss drugs . However, sales rose 59% for Mounjaro quarter over quarter and were up 140% for Zepbound as Lilly saw better pricing. Meanwhile, analysts see several events on the horizon that could further boost Lilly's shares in coming months.

Persons: Eli Lilly, Bansal, Lilly, Carter Gould, Lilly's headwinds, Novo's, Wells Fargo's Bansal, Evan David Seigerman, Chris Schott, Schott, Lilly's Organizations: Novo Nordisk, Wells, Barclays, Nordisk, BMO Capital Markets, Food and Drug Administration Locations: Wells Fargo, Lilly's, Wednesday's

☆ Eli Lilly reports earnings Thursday. Here's what Wall Street is watching
▼ + stars: | 2024-08-07 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. While Eli Lilly's stock remains up about 32% year to date, concerns about increasing competition in the category have resulted in a nearly 16% decline for Lilly shares over the past month. Eli Lilly is making similar attempts with Zepbound, but its launch is at an earlier stage than Wegovy. Second-quarter sales of Ozempic, Novo's diabetes treatment, rose 4% from the first quarter, while Wegovy revenue grew 24% quarter over quarter. Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness.

Persons: Eli Lilly, Eli, Lilly, Wells, Mohit Bansal, Ozempic, Bansal, Emily Field, David Song, Song, Chris Schott, Schott Organizations: Novo Nordisk, LSEG, Lilly's, Management, Food and Drug Administration, Barclays, Tema, JPMorgan Locations: Wells Fargo, IQVIA, Amgen, MariTide, Novo, CagriSema

☆ Earnings playbook: Disney and this industrial giant are among companies slated to report this week
▼ + stars: | 2024-08-04 | by ( Fred Imbert | ) www.cnbc.com time to read: +4 min

More than 70 S & P 500 names are slated to report this week, including Disney and Caterpillar . Tuesday Uber Technologies is set to report earnings before the bell. This quarter: The ride-hailing giant is expected to report a 70% year-over-year increase in earnings, LSEG data shows. What history shows: Uber has beaten earnings expectations in six of the last seven quarters, according to data from Bespoke Investment Group. Wednesday Walt Disney is set to report earnings before the open.

Persons: Eli Lilly, Benjamin Black, Uber, Walt Disney, Wells, Steven Cahall, LLY, Eli Lilly's Organizations: Disney, Caterpillar . Pharmaceutical, behemoth, CNBC, Technologies, Investors, Autonomous Vehicle, Deutsche Bank, Investment, Caterpillar, JPMorgan Locations: California

☆ Here are JPMorgan's top drug stock picks into earnings
▼ + stars: | 2024-07-29 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

JPMorgan is eyeing a few drug manufacturers ahead of their earnings reports as investors continue to sell out of major technology firms. This backdrop has analyst Chris Schott reviewing JPMorgan's top pharmaceutical and biotechnology stocks, which includes "stories that have clear upside potential to longer-term estimates" like Eli Lilly and Merck. Eli Lilly Pharmaceutical company Eli Lilly made the list. Schott said the firm is somewhat below consensus Wall Street estimates for Eli Lilly heading into second-quarter results on Aug. 8. LLY YTD mountain Eli Lilly stock.

Persons: Johnson, Merck —, Chris Schott, Eli Lilly, Merck, Schott, —, Regeneron Organizations: JPMorgan, Dow Jones, Johnson, Merck, US Major Pharma, Schott, FactSet, Pharmaceuticals Locations: Mounjaro, Novo

☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
▼ + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com time to read: +10 min

Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.

Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey

☆ Eli Lilly to invest another $5.3 billion in Indiana plant to expand Mounjaro, Zepbound supply
▼ + stars: | 2024-05-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Eli Lilly on Friday said it is investing another $5.3 billion in a manufacturing plant in Lebanon, Indiana, to boost supply of its highly popular weight loss drug Zepbound, diabetes treatment Mounjaro and other medicines. That makes it Eli Lilly's largest manufacturing investment in its nearly 150-year history, the company's CEO David Ricks said in a statement. Eli Lilly expects the Lebanon site to start making medicines toward the end of 2026, and scale up operations through 2028. The plant will specifically increase Eli Lilly's capacity to manufacture the active ingredient in Zepbound and Mounjaro, called tirzepatide.

Persons: Eli Lilly’s, Eli Lilly, Eli Lilly's, David Ricks, Ricks, Anat Ashkenazi, Ashkenazi Organizations: Nexus Pharmaceuticals, Investors Locations: New York City, Lebanon , Indiana, U.S, Lebanon, Indiana, Europe, North Carolina, Ireland, Germany

☆ Healthy Returns: Eli Lilly, Novo Nordisk make progress toward boosting weight loss drug supply
▼ + stars: | 2024-05-07 | by ( Eduardo Munoz | ) www.cnbc.com time to read: +3 min

A highly popular group of weight loss and diabetes drugs is still hard to find in the U.S. The dominant manufacturers of those treatments, Eli Lilly and Novo Nordisk , are making progress toward changing that. Patients using current autoinjectors for weight loss and diabetes drugs go through four different pens per month. Eli Lilly expects supply for Zepbound, Mounjaro and other incretin drugs to remain "quite tight" in the near- to mid-term as demand remains high, Ashkenazi said. On the day Eli Lilly reported earnings, shares of the company jumped more than 5% on the raised guidance and supply updates.

Persons: Eli Lilly, Anat Ashkenazi, There's, Ashkenazi, David Ricks, —, Lilly, Chris Schott Organizations: U.S, Novo Nordisk, Nexus Pharmaceuticals, JPMorgan Locations: North Carolina, Indiana, Ireland, Germany, Europe, U.S

☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
▼ + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S

☆ Eli Lilly soars 8% after Q1 earnings reveal surging popularity for its Zepbound weight-loss drug
▼ + stars: | 2024-04-30 | by ( Matthew Fox | ) www.businessinsider.com time to read: +4 min

The world's biggest healthcare company said it experienced surging demand for its GLP-1 Zepbound weight loss drug. Eli Lilly raised its 2024 revenue guidance, suggesting that the supply shortage of its weight loss drug may soon ease. The results showed soaring demand for its GLP-1 weight loss drug Zepbound, and the revenue guidance increase suggests that ongoing supply shortages of the drug may soon ease. "We have approximately 67% access in the commercial segment," Eli Lilly CFO Anat Ashkenazi said on the company's earnings call. Eli Lilly is looking to expand its indications of Zepbound so it can treat more health problems, including sleep apnea.

Persons: Eli Lilly, —, Zepbound, David Ricks, Eli Lilly's, Anat Ashkenazi, Ashkenazi, LLY, JPMorgan, JPMorgan isn't Organizations: Service, JPMorgan Locations: America

☆ Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, Mounjaro
▼ + stars: | 2024-04-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street's expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range. Shares of Eli Lilly jumped almost 8% in premarket trading Tuesday. With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, LSEG, They're Organizations: Analysts, LSEG Locations: San Diego , California, U.S

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Most doses of Eli Lilly 's highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according to an update on the Food and Drug Administration's drug shortage database on Wednesday. All doses of Zepbound and Mounjaro besides the 2.5-milligram versions of both treatments are in a shortage. "We recognize this situation may cause a disruption in peoples' treatment regimens and areworking with purpose and urgency to help meet the surge in demand," an Eli Lilly spokesperson said in a statement to CNBC. The company expects its investments in manufacturing and supply capacity "to progressively increase production of our medicines throughout 2024 and beyond," they added.

Persons: Eli Lilly’s, Eli Lilly Organizations: Food, Novo Nordisk, CNBC Locations: New York City, U.S

☆ Here are Friday's biggest analyst calls: Apple, Tesla, Netflix, Marvell, Ollie's, Snowflake, Eli Lilly, Krispy Kreme & more
▼ + stars: | 2024-04-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

"We are raising our YE'24 NFLX target price $65 to a street-high $765 driven primarily by a combo of higher '24 and beyond subscriber/ARPU forecasts." "We are upgrading Ollie's Bargain Outlet to a Buy from a Hold rating while raising our price target to $90 from $80, implying 26% upside from current levels." We cut our price target from $2 to $1, still giving ATUS the highest multiple in Cable as optionality. "We are raising our already Street High $330 YE'24 target price $60 to $390 driven primarily by higher premium and to a lesser extent ad supported ARPU forecasts." Jefferies adds Pepsi to the franchise picks list Jefferies said it sees opportunity internationally for Pepsi and raised its price target to $209 per share from $199.

Persons: Marvell, it's, Bernstein, Mizuho, Wells, Piper Sandler, Krispy, JPMorgan, Eli Lilly, LLY, Stifel, Rosenblatt, Snowflake, Jefferies, underperform KBW, Daiwa, Tesla, KBW, Monness Crespi Hardt Organizations: Netflix, Bank of America, Apple, Amazon Web Services, RBC, Eaton, Piper, JPMorgan, Technologies, Cable, Spotify, BMO, Royal Bank, Pepsi, Fox, Fox News, Digital, Citi, Express, American Express Locations: NY, McDonald's, USA, Toronto, Snowflake, U.S

☆ Morgan Stanley ponders if Eli Lilly could be the first $1 trillion pharma stock on weight loss boom
▼ + stars: | 2024-02-16 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +3 min

On Friday, Flynn raised his price target on Lilly shares to $950 from $805. With Lilly's stock closing Thursday at $757.78, the target suggests 25% more upside ahead. LLY 1Y mountain Eli Lilly shares over the past year. "LLY is establishing high barriers to entry in the diabesity market," Flynn said, adding that this is what contributes to its higher valuation. Phase 3 data is expected on orforglipron in 2025, which Flynn sees as a catalyst for the stock to go higher.

Persons: Eli Lilly, Morgan Stanley, Terence Flynn, Flynn, Lilly, Mounjaro, — CNBC's Michael Bloom Organizations: Novo Nordisk Locations: diabesity

☆ Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
▼ + stars: | 2024-02-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +8 min

Victoria Klesty | ReutersThe insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly , have said supply woes likely won't go away anytime soon, as the popularity of those medicines continues to soar. Some Wall Street analysts project that the weight loss drug market could be worth $100 billion by the end of the decade. But both Novo Nordisk and Eli Lilly gave updates on positive supply developments to investors over the last week. Other forms of weight loss drugs could helpAlternative forms of weight loss drugs could also help alleviate supply constraints in the future.

Persons: Victoria Klesty, Eli Lilly, Cantor Fitzgerald, Louise Chen, Nordisk's Wegovy, Eli Lilly's Zepbound, Goldman Sachs, Jeff Friedman, Novo, Mike Segar, Eli, Catalent, Yves Herman Yves Herman, TD Cowen, Michael Nedelcovych, Anat Ashkenazi, Cantor Fitzgerald's Chen, Morgan Stanley, Eli Lilly's, George Frey Organizations: Novo Nordisk, CNBC, Nordisk's, University of Florida, Pfizer, AstraZeneca, Roche, Food, Nordisk, Company, FDA, Novo Holdings, Wegovy, REUTERS, Reuters, U.S Locations: Oslo, Norway, Novo, U.S, Branchburg , New Jersey, Brussels, Belgium, Catalent, Concord , North Carolina, North, Germany, Indiana, Denmark, France

Still, Eli Lilly and Novo Nordisk appear to be making some encouraging progress. Eli Lilly wasn't the only weight loss drug producer to see positive supply developments in the last week. Novo Holdings, which owns almost 77% of the voting shares in Novo Nordisk, said Monday it will acquire drug manufacturer Catalent in a $16.5 billion deal. Novo Nordisk will then buy three of Catalent's manufacturing plants from Novo Holdings for $11 billion. Tema in November launched an ETF whose key holdings include companies benefiting from the hype around weight loss drugs.

Persons: Eli Lilly, Anat Ashkenazi, Incretin, Eli Lilly's, Ashkenazi, Eli Lilly wasn't, Yuri Khodjamirian, Danish drugmaker Organizations: Novo Nordisk, Holdings, Wegovy, Novo Holdings, CNBC, Tema, Nordisk, Reuters Locations: North Carolina, Novo, Tema, Brussels, Danish, U.S

☆ Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
▼ + stars: | 2024-01-24 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Lilly's Mounjaro and Zepbound both use tirzepatide as an active ingredient, but Mounjaro is indicated for type 2 diabetes, while Zepbound aids weight loss. A rich valuation LLY 1Y mountain Eli Lilly shares over the past year. But even good news about Zepbound's launch might not be enough to propel Lilly's stock higher. Goldman's Shibutani has a neutral rating on Lilly shares and a price targe of $600, which implies shares could fall nearly 5% from they started the week. He has a buy rating on Lilly shares, and expects the stock could hit $700 over the next 12 months.

Persons: Eli Lilly's, Lilly, Goldman Sachs, Chris Shibutani, IQVIA, Shibutani, Lilly's, Mounjaro, Eli Lilly, Geoff Meacham, NASH, Meacham, there's, Morgan Stanley, Terence Flynn, Flynn, Morgan Stanley's, Michael Bloom Organizations: Food and Drug Administration, Zepbound, Novo Nordisk's, Medicare, Bank of America, Novo Nordisk, Bank of, FDA, CNBC Locations: Indianapolis, Mounjaro

☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
▼ + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.

Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23

A sign is pictured outside an Eli Lilly and Company pharmaceutical manufacturing plant at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Incretins are peptide-based drugs such as Mounjaro that mimic gut hormones to suppress appetite and stimulate insulin secretion. Lilly said it had announced investments of more than $11 billion in global manufacturing in the past three years. Major production sites that Lilly runs outside of its U.S. home market are in Ireland, France, Spain, Italy and China. The new Alzey site will employ up to 1,000 highly skilled workers such as engineers, technicians and scientists, said Lilly.

Persons: Eli Lilly, Mike Segar, Lilly, Karl Lauterbach, Lauterbach, generics, Patrick Wingrove, Matthias Williams, Jason Neely, David Evans Organizations: Company, REUTERS, Rights, Reuters, U.S ., Novo Nordisk, European Union, pharma, The U.S ., Thomson Locations: Branchburg , New Jersey, Germany, Alzey, U.S, United States, Danish, Berlin, Fegersheim, France, European, Indiana , North Carolina, Limerick, Ireland, Spain, Italy, China, The U.S

☆ Here are Thursday's biggest analyst calls: Amazon, Sunrun, Qualcomm, Eli Lilly, SolarEdge, Estée Lauder and more
▼ + stars: | 2023-11-02 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: Bank of America reiterates Qualcomm as buy Bank of America said it's standing by its buy rating on the stock after its earnings report Wednesday. Citi reiterates Eli Lilly as buy Citi said it sees further upside after the company's earnings report Thursday. RBC downgrades Estée Lauder to sector perform from outperform RBC downgraded the stock after the company's earnings report. Pivotal upgrades Roku to hold from sell Pivotal upgraded the stock after its earnings report Wednesday. " Guggenheim downgrades SolarEdge to neutral from buy The firm said it's "giving up" on its positive stance on the stock.

Persons: RUN's, Taylor Morrison, WK Kellogg, Truist, Amgen, it's, Citi, Eli Lilly, Janus Henderson, underperform KBW, Estée Lauder, F1Q, Bernstein, Hess, CVX, Guggenheim, SolarEdge, Stifel Organizations: Bank of America, Qualcomm, HSBC, Amazon, BMO, Toll, M.D.C . Holdings, JPMorgan, Health, of America, UBS, Eastman Chemical, Citi, Management, RBC, Chevron Locations: Ecommerce, China, U.S

☆ Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
▼ + stars: | 2023-10-23 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. Last month, the firm made a case for there being a $150 billion to $200 billion opportunity for these drugs. At the moment, private insurance coverage isn't a guarantee for those seeking weight loss treatment, and the federal Medicare program doesn't cover weight loss drugs at all. Lilly expects the Food and Drug Administration to approve this drug to treat obesity by the end of this year.

Persons: Seamus, Fernandez, Andrew Baum, Goldman Sachs, Chris Shibutani, Shibutani, Eli Lilly, Lilly Organizations: Monday, Citi, Wegovy, Food and Drug Administration Locations: GLP

Search resuls for: "Incretin"

25 mentions found